Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
20%
Ph not_applicable
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Other(1)

Detailed Status

Completed2
Not yet recruiting1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (50.0%)
N/A1 (50.0%)

Trials by Status

completed240%
not_yet_recruiting120%
recruiting120%
unknown120%

Recent Activity

1 active trials
Showing 5 of 5
completedphase_2

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

NCT03947216
not_yet_recruiting

Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

NCT06754553
recruiting

Tracking Atrial Fibrillation After Intensive Care Admission

NCT05229211
unknown

Artificial Intelligence (AI) Enabled, Cloud-based ECG Diagnostic Solution (ZBPro) Feasibility Testing

NCT06013917
completednot_applicable

Preoperative Anxiety and Music Therapy

NCT03171753

Clinical Trials (5)

Showing 5 of 5 trials
NCT03947216Phase 2

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Completed
NCT06754553

Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Not Yet Recruiting
NCT05229211

Tracking Atrial Fibrillation After Intensive Care Admission

Recruiting
NCT06013917

Artificial Intelligence (AI) Enabled, Cloud-based ECG Diagnostic Solution (ZBPro) Feasibility Testing

Unknown
NCT03171753Not Applicable

Preoperative Anxiety and Music Therapy

Completed

All 5 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
5